<DOC>
	<DOCNO>NCT00043355</DOCNO>
	<brief_summary>The purpose research study test safety effectiveness inhale Interferon gamma-1b ( IFN-g 1b ) , administer 48 week combination oral antibiotic may administer 72 week treatment lung infection cause bacterium call Mycobacterium avium complex . FDA approve Interferon gamma-1b use patient MAC infection lung , purpose study.Interferon gamma-1b similar protein play important role establish maintain protective immune response variety microorganism .</brief_summary>
	<brief_title>Safety Efficacy Inhaled Interferon Gamma-1b Pulmonary MAC Infection</brief_title>
	<detailed_description>Laboratory research show mouse form interferon gamma effective treating mouse infection cause bacteria similar MAC well MAC infection .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Mycobacterium avium-intracellulare Infection</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>Male female patient , 18 year age old , bacteriologically radiographically confirm pulmonary MAC infection treat infection least 6 month within previous 2 year , well patient moderate severe pulmonary disease due MAC , previously treat infection . Patients recurrent pulmonary MAC infection previous successful treatment pulmonary MAC disease also eligible . In addition , various laboratory test must confirm condition . Patients positive HIV extrapulmonary ( general , outside lung ) infection MAC . Other precondition relate health condition exist factor inclusion exclusion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>pulmonary</keyword>
	<keyword>mycobacterium avium complex infection</keyword>
	<keyword>MAC</keyword>
	<keyword>nontuberculous</keyword>
	<keyword>mycobacteria</keyword>
	<keyword>lung</keyword>
</DOC>